Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects

Lersivirine (UK-453,061) is a new nonnucleoside reverse transcriptase inhibitor currently being developed as a treatment for human immunodeficiency virus type 1 infection. Lersivirine shows potent activity against wild-type and clinically relevant drug-resistant strains. Previous studies have demons...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vourvahis, Manoli, Langdon, Grant, LaBadie, Robert R., Layton, Gary, Ndongo, Marie-Noella, Banerjee, Subhashis, Davis, John
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2012
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3264271/
https://ncbi.nlm.nih.gov/pubmed/22123705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00572-11
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky